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Abstract
Background Basal cell carcinomas (BCCs) are common malignant skin tumors. Despite
having a significant invasion capacity, they metastasize only rarely. Our aim in this study
was to detect the expression patterns of the NM23-H1, NDRG1, E-cadherin, RHOGDI2,
CD82/KAI1, MKK4, and AKAP12 metastasis suppressor proteins in BCCs.
Methods A total of 96 BCC and 10 normal skin samples were included for the
immunohistochemical study. Eleven frozen BCC samples were also studied by quantitative
real time polymerase chain reaction (qRT-PCR) to detect the gene expression profile.
Results NM23-H1 was strongly and diffusely expressed in all types of BCC. Significant
cytoplasmic expression of NDRG1 and E-cadherin was also detected. However, AKAP12
and CD82/KAI1 expression was significantly decreased. The expressions of the other
proteins were somewhere between the two extremes. Similarly, qRT-PCR analysis showed
down-regulation of AKAP12 and up-regulation of NM23-H1 and NDRG1 in BCC.
Morphologically aggressive BCCs showed significantly higher cytoplasmic NDRG1
expression scores and lower CD82/KAI1 scores than non-aggressive BCCs.
Conclusion The relatively preserved levels of NM23-H1, NDRG1, and E-cadherin proteins
may have a positive effect on the non-metastasizing features of these tumors.
Introduction
Basal cell carcinoma of the skin (BCC), a common human
carcinoma, tends to be locally invasive and metastasizes
only rarely.1 Despite the low metastasizing ability, these
lesions show significant invasion capacity if neglected.2
This unusual predisposition makes BCC an interesting
biological model for invasion and metastasis.
Metastasis is a complex biological process and is con-
trolled by various mechanisms. One important mecha-
nism is provided by metastasis suppressor proteins
(MSPs). MSPs inhibit or suppress metastasis without
any effect on cell proliferation and affect different steps
of the complex metastasizing process. To date, more
than 30 MSPs have been identified.3 In this study, we
investigated the expression patterns of seven well-defined
important MSPs, including NM23-H1, NDRG1, E-cadh-
erin, RHOGDI2, CD82/KAI1, MKK4, and AKAP12 in
BCCs.
NM23-H1 is the first described MSP and is downregu-
lated in several metastatic cell lines and in a group of
human carcinomas.4 NM23-H1 gene encodes a nucleo-
side diphosphate kinase A. Although the metastasis sup-
pressor mechanism of NM23-H1 is not clear, its
interaction with kinase suppressors of RAS and, as a
result, alteration of the MAPK signaling pathway is a
probable mechanism.3 It has also recently been suggested
that it suppresses metastasis by inhibiting the expression
of EDG2 (lysophosphatidic acid receptor).5
NDRG1 (N-myc downstream regulated 1) is a member
of the NDRG family of proteins and has been shown to
reduce metastasis in colon, breast, and prostate neo-
plasms.6 Although the metastasis suppressor mechanism
of NDRG1 is not clear, the interaction with the cell–cell
adhesion molecules b-catenin and E-cadherin might be a
possible mechanism.7,8
E-cadherin is a well-known cell–cell adhesion protein,
and loss of its expression plays important roles in tumor
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invasion and metastasis.9,10 It also functions as a negative
regulator of the canonical WNT signaling pathway.
E-cadherin has been extensively studied in human tumors,
including BCCs.11,12
RHOGDIs (Rho GDP-dissociation inhibitors) make up
a small group of proteins that negatively control
RhoGTPases, which play important roles in cancer and
metastasis.13 RHOGDI2 acts as an MSP in bladder
tumors and probably in other types of epithelial tumors.14
However, RHOGDI2 may have cancer or tissue-specific
functions in tumor suppression, while it might promote
cancer invasiveness in a minority of human cancers. 14,15
The CD82/KAI1 protein, also called TSPAN27, is a
member of the tetra-spantin family, which has important
roles in adhesion, motility, and tumor progression.16,17 It
was initially demonstrated as an MSP in prostate carci-
noma.18 The prognostic importance of this protein was
then demonstrated in other human cancer types.17,19,20
Mitogen-activated protein kinase kinase 4 (MKK4) is a
component of MAP kinase in stress-activated protein
kinase signaling.21,22 It was identified as an MSP in pros-
tate and ovarian cancer.23,24 Although the tumor or metas-
tasis suppressor function of MKK4 is generally accepted,
there are also some clues that it has pro-oncogenic roles.22
AKAP12, also called SSeCKS/Gravin, is a scaffold pro-
tein and functions as a binding partner of protein kinase C
and A, calmodulin, F-actin, cyclins, Src, and phospholip-
ids.25 Significant clinical and experimental evidence has
shown that AKAP12 is an important tumor and metastasis
suppressor.25 AKAP12 expression is downregulated in var-
ious solid human cancers and some leukemias.25,26
The significance of MSPs in BCC is not well known due
to the limited number of studies (Table 1). Our aim was to
demonstrate the distribution and expression of the seven
important MSPs in BCC. We also tried to determine the
relationship between protein expression levels, p53 status,
and well-known clinicopathological parameters.
Materials and methods
Study group
A total of 96 BCCs from 92 patients (47 male/45 female) were
included in this study. All patients were Caucasian, and the mean
age was 66.3  13.4 years. All lesions were excised from the
head and neck area except for five lesions from the trunk. Normal
epidermis samples adjacent to the BCCs (NE-BCC) and 10 non-
lesional, histopathologically confirmed normal skin tissues (N)
were also studied. As there is no easy way to subclassify BCCs
because of their wide and heterogeneous morphological
spectrum, we used the criteria summarized by Carr et al. for
classifying our group.27 Two major tumor groups were created
and immunohistochemically scored to establish the differential
expression patterns and contribution of the proteins:
1 Morphologically non-aggressive BCC types, including
nodular, adenoid, superficial, and mixed carcinomas with less
than 50% infiltrative pattern (n = 68).
2 Morphologically aggressive BCC types, including infiltrative
BCCs with/without desmoplasia and mixed carcinomas with
more than 50% infiltrative pattern (n = 28).
Clinicopathological features
The conventional clinicopathological parameters, including
maximum diameter of the tumor, invasion depth, perineural
invasion, anatomical invasion (Clark’s) level, and local
recurrences, were investigated. Tumor-associated
inflammation was graded as previously described by
Kaur et al.28
Immunohistochemistry
The classical, labeled streptavidin–biotin immunohistochemistry
technique (UltraVision/DAB-Thermo Scientific, Waltham, MA,
USA) was used for immunostaining of the slides. All steps of
immunostaining were carried out by specific capillary cover-
plate technology in a Thermo-Shandon Sequenza (Waltham,
MA, USA) manual staining device. The negative control was
performed by skipping the primary antibody step. Vendors,
incubation time, antigen retrieval solutions, and positive
controls are demonstrated in Table 2.
Immunohistochemical analyses
The immunohistochemistry results were analyzed
semiquantitatively by using an immunohistochemical
histological score (HSCORE) that included both the intensity
and proportional distribution of specific staining. Based on a
specific method described by McCarty et al., the HSCORE
has been formulated as HS = ∑ (Pi 9 i/100), where Pi
indicates the percentage of stained cells (0–100%) at each
intensity and i shows the intensity of staining and ranges from
no staining (0 points) to strong staining (3 points).29 The
calculated HSCOREs were between 0 (no staining) and 300
(strong-diffuse staining) points. All calculations were performed
with the Microsoft Office Excel program using a simple
macro. After evaluating the whole slide for specific staining, a
minimum of five to seven randomly selected areas at medium
power magnification (920) in normal and neoplastic tissues
were analyzed for HSCORE. Nuclear (nuc) and cytoplasmic
(cyt) expressions were evaluated separately for NM23-H1,
MKK4, RHOGDI2, and NDRG1. Only membranocytoplasmic
staining of E-cadherin, AKAP12, and CD82, and nuclear
staining of p53 were accepted as positive.
Statistical analysis
Statistical analyses were performed using the PASW Statistics
18 software (Chicago, IL, USA). The “Bonferroni correction”
was applied for reducing the false-positive results. The
differences between the HSCOREs of the groups were studied
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with the non-parametric Mann–Whitney U test. The correlation
between the parameters was investigated by Spearman’s
correlation test, and r ≥ 0.25 and P ≤ 0.05 were accepted as a
significant correlation.
Quantitative real-time polymerase chain reaction study
group
Quantitative real-time polymerase chain reaction (qRT-PCR)
experiments were performed for frozen tissue consisting of 11
BCCs, three normal non-lesional skins, and eight normal skins
adjacent to the BCCs. All tissues were re-confirmed by frozen
sections before RNA isolation.
Quantitative real-time polymerase chain reaction
Total RNA was isolated from tissues using commercial RNA
extraction kit (Fibrous Tissue kit; Qiagen, Hilden, Germany) in
accordance with the manufacturer’s instructions. A total of
500 ng of total RNA was reverse-transcribed using oligo-dT
primers for cDNA synthesis. qRT-PCR experiments were
performed using the SYBR Green chemistry in 96-well reaction
plates with optical caps (Bioplastics, Landgraaf, Netherland) in an
MX3005P (Strategene-Agilent, Santa Clara, CA, USA)
thermocycler. GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) and HPRT1 (hypoxanthine phosphoribosyl-
transferase 1) genes were selected as reference genes. The
qRT-PCR reaction contained 10 ll 2 9SYBR Green PCR Master
Mix (Finnzyme-Thermo, Waltham, MA, USA), forward and
reverse primers at optimized concentrations of 300 nM (150 nM
for NDRG1 primers, 200 nM forMKK4 primers), 2 ll cDNA
template (500 ng/ml), and PCR grade water up to a final volume
of 20 ll. The fluorescence data were also confirmed by melt-
curve analysis for the specificity of the product. The primers used
in this study are documented in Table 3.
Quantitative real-time polymerase chain reaction data
analysis
Data analysis was performed with the free-use REST© 2009
(Qiagen) software, which gives reliable results in small study
groups.30 This software uses the classic formulation
Ratio ¼ ðEtargetÞDCP target ðcontrol sampleÞ=ErefÞDCP ref ðcontrol sampleÞ
whereE is the amplification efficiency of the primers and CP is the
cycle threshold, and shows both fold changes and standard errors
between the controls and the samples. Statistical significance
between the groups was evaluated by the Pair Wise Fixed
Reallocation Randomization Test© using the REST software.
Results
Immunohistochemical staining
In normal epidermis (N), all of the proteins were
expressed at various intensities. NDRG1, E-cadherin,
RHOGDI2, and cytoplasmic NM23-H1 positivity wasTa
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strong and easily detectable. However, nuclear NM23-H1
was only seen in the basal layers of the epidermis.
AKAP12, CD82/KAI, and cytoplasmic MKK4 were
stained at medium intensities. Nuclear staining of MKK4
was very weak and not easily detectable. NE-BCC
showed more heterogeneous positivity with all antibodies
when compared to the normal epidermis.
In BCCs, both cytoplasmic (NDRG1cyt) and nuclear
NDRG1 (NDRG1nuc) positivity were homogeneous (Fig.
2c, d). NDRG1cyt was seen in all BCCs. However, only
74 of 96 (77%) BCCs showed nuclear positivity. Simi-
larly, NM23-H1 cytoplasmic expression (NM23-H1cyt)
was also strong and diffused, except in two BCCs
(97.9%) (Fig. 2a, b). Nuclear expression of NM23-H1
was weaker and expressed in 73 of 96 (76%) cases. E-
Cadherin antibody was represented by both membranous
and cytoplasmic positivity except in seven BCCs (92.7%)
(Fig. 2e, f). Nuclear staining was seen very rarely and usu-
ally in strongly stained areas. CD82/KAI and AKAP12
positivity was significantly reduced and only seen in focal
areas of the BCCs in 14 (15.1%) and 21 of 96 (21.8%)
cases, respectively (Fig. 3c–f). MKK4 immunostaining of
neoplastic tissues was weak/medium cytoplasmic positive
in 73 (76%) and weak nuclear positive in only 35 (36.4%)
cases (Fig. 3a,b). The nuclear expression was more evident
in normal tissues. Although RHOGDI2 staining showed
cytoplasmic positivity (RHOGDI2cyt) in 89 of 96 (92.7%)
cases, the intensity was significantly reduced (Fig. 2g,h).
Nuclear expression (RHOGDI2nuc) was very weak and
heterogeneously in 59 (61.4%) of 96 BCCs.
HSCORES
The HCORES of the groups are demonstrated in the
boxplot graph (Fig. 1).
Statistical results
As the tumor microenvironment changes are part of carci-
nogenesis, we evaluated the difference between the NE-
BCC and normal non-lesional (N) skin. Although there
was no statistical difference for RHOGDI2cyt, NM23-
H1cyt/nuc, CD82, and MKK4 cyt/nuc scores between the
two groups, the other markers showed a significant reduc-
tion in NE-BCC (P ≤ 0.05).
When normal epidermis was compared to BCCs, all of
the scores except for NM23cyt/nuc were significantly lower
in the tumor groups (P ≤ 0.01). Similarly, when NE-BCC
was compared to BCCs, all of the markers except for
NM23-H1cyt and NDRG1cyt indicated significantly
reduced scores (P ≤ 0.01) in the BCC group. Furthermore,
NM23-H1nuc scores were higher in BCCs than in NE-BCC.
Table 2 Primer antibodies used in this study
Antibody Vendor Dilution Antigen retrieval Incubation Control tissue
RHOGDI2 Abcam 1/100 Citrat; pH 6 Overnight Tonsil
NM23-H1 Abcam 1/200 No Overnight Ductal carcinoma, breast
MKK4 Novocastra; Leica 1/20 Citrat; pH 6 Overnight Ductal carcinoma, breast
CD82 Novocastra; Leica 1/20 Citrat; pH 6 Overnight Tonsil
AKAP12 Atlas 1/100 Citrat; pH 6 Overnight Testis
NDRG1 Santa Cruz 1/100 EDTA; pH 9 Overnight Placenta
E-cadherin Cell Signaling 1/100 Citrat; pH 6 Overnight Adenocarcinoma, colon
P53 Thermo 1/100 Citrat; pH 6 Overnight Adenocarcinoma, colon
Table 3 qRT-PCR primer sequences used in this study
Gene F R
GAPDH 5′-AGGTGAAGGTCGGAGTCAAC-3′a 5′-GGGTCATTGATGGCAACA-3′
HPRT1b 5′-GCTGACCTGCTGGATTACAT-3′ 5′-CCCTGTTGACTGGTCATTAC-3′
KAI1/CD82 5′-AGCAGAACCCGCAGAGTCCT-3′ 5′-CTTCCACGAAACCAGTGCAG-3′
MAP2K4c 5′-AGTGGACAGCTTGTGGACTCT-3 5′-AACTCCAGACATCAGAGCGGA-3′
NM23 (NME1) 5′-CCTGAAGGACCGTCCATTCT-3′ 5′-CCGTCTTCACCACATTCAGC-3′
E-cadherin (CDH1) 5′-GTCCTGGGCAGAGTGAATTT-3′ 5′-TCTGTGCCCACTTTGAATCG-3′
AKAP12 5′-TCACAGAGGTTGGACAGAGA-3′ 5′-GTGAACAACCGCTGACTTAG-3′
RHOGDI2 (ARHGDIB) 5′-CCTCCACCACAGAAGTCCCT-3′ 5′-GCTTTCGGATCTGTCACCAC-3′
NDRG1 5′-CAAGATCTCAGGATGGACC-3′ 5′-GACCACTTCCACGTTACTC-3′
aMol Cancer 2010; 9: 226.
bDesigned by Dedeoglu BG, PHD.
cGynecol Oncol 2007; 105: 312–320.
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Morphologically aggressive BCCs expressed signifi-
cantly higher NDRG1cyt scores (P = 0.001) and lower
CD82/KAI1 scores (P = 0.048).
BCCs with perineural invasion showed lower nuclear
NM23-H1 levels (P = 0.01). Recurrent BCCs expressed
higher RHOGDI2nuc levels (P = 0.01) when compared to
the non-recurrence group.
Correlation analysis
In the BCC group, there were significant correlations (P =
0.01 level) between several markers as follows: NM23-
H1nuc-NM23-H1cyt (r = 0.442); AKAP12-RHOGDI2cyt
(r = 0.333); AKAP12-NDRG1cyt (r = 0.280); E-cadherin-
RHOGDI2cyt (r = 0.303); E-cadherin-NDRG1cyt (r =
0.413); RHOGDI2nuc-RHOGDI2cyt (r = 0.405); RHO-
GDI2nuc-MKK4cyt (r = 0.294); NDRG1nuc-NDRG1cyt
(r = 0.356); and MKK4nuc-MKK4cyt (r = 0.365). There
were also significant negative correlations between
AKAP12 and inflammation (r = 0.275; P = 0.007).
A randomly selected subgroup of 44 BCCs from the
main group was stained with p53 primary antibody to
establish the correlation between MSPs and p53. We
detected only a negative correlation with RHOGDI2cyt
(r = 0.316; P = 0. 037).
Relative expression software tool (REST) analysis of
quantitative real-time polymerase chain reaction data
BCCs were compared to both the normal non-lesional
skin tissue and the skin adjacent to neoplasia groups. We
found significant upregulation of NM23 (1.4-fold,
P = 0.032) and downregulation of AKAP12 (1.2-fold;
P = 0.006) when BCC was compared to normal skin.
(a) (b)
(c) (d)
(e) (f)
(g)
Figure 1 Boxplot graphics of the
groups. (a) NM23-H1; (b) NDRG1;
(c) E-cadherin; (d) RHOGDI2; (e)
MKK4; (f) CD82; (g) AKAP12. The
protected levels of NM23-H1 (a),
NDRG1 (b) and E-cadherin (c) in
BCCs are clearly demonstrated in
boxplot graphics. Conversely,
significant downregulation or lost of
CD82 (f) and AKAP12 (g) HSCOREs
have attracted attention in the tumor
group. For RHOGDI2 (d) and MKK4
(e) HSCOREs, although the
downregulation is seen in both
nuclear and cytoplasmic scores,
reduction of nuclear HSCOREs are
more significant. A-BCC, aggressive
BCC; BCC, basal cell carcinoma; NA-
BCC, non-aggressive BCC; NE-BCC,
normal epidermis adjacent to BCC.
* and  demonstrate more than one
case with similar HSCORE
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NDRG1 showed statistically significantly higher levels
(2.2-fold, P = 0.001) in BCC when compared to the skin
adjacent to the neoplasia, similar to the immunohisto-
chemical results.
Discussion
Invasion and metastasis are the most important hallmarks
of cancer and well-known clinical signs of a poor progno-
sis.31,32 BCCs display all the hallmarks of cancer,
including invasion, with the exception of metastasis. To
date, the question of why BCCs metastasize only rarely
has not been adequately answered. A possible but
unsupported explanation for this question is the strict
stromal dependence of BCC.33 In this study, we examined
the contribution of the MSPs in the non-metastasizing
feature of BCCs and focused on seven well-known proteins.
We detected that NM23-H1 HSCOREs were protected
in BCCs, and mRNA level of NM23-H1 was higher in
BCCs than in normal skin. Similarly, Ro and Jeong and
(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 2 Significant NM23-H1
positivity is seen in both nodular (a)
and infiltrative basal cell carcinomas
(BCCs). (b). NM23-H1
immunostaining highlights basal
palisading cells in nodular type BCC.
(c,d) Similar to NM23, strong
NDRG1 expression is detected in
BCCs. (e,f) E-cadherin expression is
protected in BCCs. (g,h) RhoGDI
expression is very weak or negative in
BCCs. The contrast between positive
inflammatory cells and carcinoma
cells is clearly demonstrated (h). (a,f,
h, 9200; b–e,g, 9100)
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Kanitakis et al. focused on the NM23-H1 protein in skin
lesions and both found medium/strong NM23-H1 positiv-
ity in all BCCs.34,35 In spite of the significant expression
of NM23-H1 in BCCs, its importance is not well known.
However, it has been shown that NM23-H1 expression is
inversely related to the metastasis status in other human
carcinomas.36 The significant NM23-H1 expression in
BCCs probably contributes to their non-metastasizing
feature.
One of the important results of this study is the demon-
stration of significant cytoplasmic NDRG1 expression in
BCC, which is also supported with the qRT-PCR study.
Although NDRG1 expression has not been studied in
BCC previously, Cangul demonstrated that human carci-
nomas expressed high levels of NDRG1 compared to
their normal counterpart,37 and the prognostic importance
of NDRG1 expression has been pointed out in various
human tumors.38–41 We also found a significant correla-
tion between NDRG1cyt (P = 0.001) and E-cadherin in
BCCs, and this relationship was reported in the literature
in colon and prostate carcinomas.8,42,43 Our data clearly
support an E-cadherin/NDRG1 pathway in human carci-
nomas.
Besides NM23-H1 and NDRG1, E-cadherin expression
was generally preserved in 92.7% of BCCs with relatively
higher HSCORES, and qRT-PCR studies also showed no
statistically significant difference from normal skin tissue.
The data from the literature and our study show that
E-cadherin positivity is expected in BCC, even if at
reduced levels compared to the normal epidermis
(Table 1).
CD82/KAI1 and AKAP12 expressions were significantly
reduced or completely lost in all morphological subtypes
of BCCs. We also detected downregulation of AKAP12
mRNA in BCC. Similar to our results, the downregula-
tion of CD82/KAI1 expression in BCCs was demonstrated
before.44 Yet, the expression pattern of AKAP12 is still
not known in BCCs, a recent article pointed out that the
methylation frequencies of the AKAP12 gene were signifi-
cantly higher in skin carcinomas than normal skin
tissue.45 CD82/KAI1 and AKAP12 probably have no
contribution to the non-metastatic features of BCCs.
(a) (b)
(c) (d)
(e) (f)
Figure 3 Normal skin adjacent to
basal cell carcinoma (BCC) expresses
medium strength nuclear and
cytoplasmic MKK4 staining. Nodular
(a) and infiltrative BCCs (b) show
reduced nuclear and cytoplasmic
staining. (c) AKAP12 expression is
clearly seen in normal epidermis and
stromal cells but not in BCCs. (d)
Weak AKAP12 staining is detected
only at squamous differentiation areas
in a BCC case. Stromal cells are also
positive in this case. CD82 expression
is not detected in nodular (e) and
infiltrative (f) BCCs except in focal
squamous differentiation areas. (a,c,f,
9100; b,d,e, 9200)
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However, we believe that these proteins are interesting
negative markers for BCCs, and further studies might
show their role in the differential diagnosis.
One of the goals of the study was to show the correla-
tion between the MSPs, and important clinicopathological
parameters and p53 in BCCs. We found AKAP12 in-
versely correlated with inflammation, together with an
inverse relationship between NM23-H1nuc and perineural
invasion. Besides these expected correlations, we found
that recurrences were correlated only with RHOGDI2nuc.
This result may be explained by the dual and unpredicted
role of RHOGDI2 in carcinomas as proposed by Griner
and Theodorescu.14 We found only an inverse correlation
between RHOGDI2cyt and p53. Although the relationship
between p53 and RHOGDI2 has not been demonstrated
previously, interaction between p53 and CD82/KAI1,
another MSP, has been reported.46–48 However, other
studies have been querying this correlation, similar to our
results.49–52
One of the major questions in this study is the contribu-
tion of MSPs to the aggressive phenotype of BCCs. We
detected upregulation of NDRG1 levels in the aggressive
phenotype (P = 0.001). Similarly, CD82/KAI levels (P =
0.048) were downregulated. In the literature, E-cadherin
levels have been shown to be downregulated in aggressive
BCCs,11,53 but this has not been supported by other stud-
ies (Table 1). These results may show a slightly different
profile of MSPs in aggressive carcinomas than non-aggres-
sive BCCs.
In conclusion, we have demonstrated differential
expression patterns for the seven MSPs in BCCs. AKAP12
and CD82/KAI1 levels were significantly reduced in
BCCs. However, NM23-H1, NDRG1, and E-cadherin
levels were minimally reduced, and they were generally
expressed in this neoplasm group. The other markers,
MKK4 and RHOGDI2, were also reduced but not lost in
BCCs. Although this is a very simplified approach, pre-
served levels of NM23-H1, E-cadherin, and NDRG1 may
contribute to the non-metastatic features of BCCs. One of
our important findings is there are plenty of significant
correlations among the MSPs. Data from this study
might reveal possible pathways between MSPs, when
combined with the current knowledge on pathways. This
relationship between these MSPs warrants further biologi-
cal and experimental pathway research.
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